Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Sodium Excess
Interventions: High Sodium, Placebo; Dietary Supplement · Other
Lead sponsor: University of Delaware; Other
Eligibility: 21 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Depression, Bipolar I Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 69
States / cities: Bentonville, Arkansas • Anaheim, California • Beverly Hills, California + 54 more

Conditions: Schizophrenia
Interventions: Iloperidone, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 28
States / cities: Anaheim, California • Bellflower, California • Costa Mesa, California + 22 more

Conditions: Cocaine Use Disorder
Interventions: SXC-2023, SXC-2023 Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Major Depressive Disorder, Irritable Bowel Syndrome
Interventions: Ganeden BC30, Placebo (sugar pill), Ganeden BC30, Placebo (sugar pill); Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Burlington, Massachusetts • Westborough, Massachusetts

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: BG00012, Placebo, Glatiramer Acetate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 72
States / cities: Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more

Conditions: Alcoholism, Cocaine Dependence
Interventions: Topiramate, placebo; Drug
Lead sponsor: Kyle Kampman; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
Interventions: Psilocybin 25mg, Placebo (active placebo); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Safety and Tolerability in Healthy Volunteers
Interventions: IgG Binding Protein LT, Placebo; Dietary Supplement
Lead sponsor: Bactolife A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Preeclampsia, Gestational Hypertension
Interventions: spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Cocaine Dependence
Interventions: Zonisamide, Placebo, Cocaine Hydrochloride, Neurocognitive and Performance Battery, Smoking Assessments; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Post-surgical Pain
Interventions: Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo; Drug
Lead sponsor: Esteve Pharmaceuticals, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more

Conditions: Dry Age-related Macular Degeneration
Interventions: QA102/Placebo, QA102, Placebo; Drug
Lead sponsor: Smilebiotek Zhuhai Limited; Industry
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 29
States / cities: Phoenix, Arizona • Mountain View, California • Pasadena, California + 25 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Nabilone, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: No Disease, Mitochondria Health, Longevity, Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult, Healthy Volunteers
Interventions: Kaempferol; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania

Conditions: Interstitial Cystitis
Interventions: Pentosan polysulfate sodium 100 mg, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 52
States / cities: Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 49 more

Conditions: Dry Eye, Eye Fatigue
Interventions: Eye Empower, Placebo; Dietary Supplement
Lead sponsor: Bio Nature Health; Industry
Eligibility: 45 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
Interventions: CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: HIV Infections, Heart Disease
Interventions: Lovaza, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer
Interventions: gemcitabine hydrochloride, tacedinaline; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 9
States / cities: Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 6 more

Conditions: Fabry Disease, Neuropathic Pain
Interventions: Gabapentin, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Sclerosis
Interventions: Isoxsuprine Hydrochloride, Placebo, Corticosteroid; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 61
States / cities: Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more

Conditions: Insomnia Disorder
Interventions: Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant-matched placebo., Flurazepam 30 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia • Crestview Hills, Kentucky

Search by objective public record fields.

Dietary Sodium, Oxidative Stress, and Pulsatile Hemodynamics

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Relapse Prevention Study in Patients With Schizophrenia

SXC-2023 Cocaine Interaction Study

Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Topiramate for Alcohol and Cocaine Dependence

Psilocybin for Treatment-Resistant Depression

Safety and Tolerability Evaluation of IgG Binding Protein LT

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

QA102 Phase II Study in Subjects With Dry AMD

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

Kaempferol Absorption and Pharmacokinetics Evaluation

Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of an Oral Supplement in Supporting Vision and Eye Health

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer

Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder